Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-sense oligo
Biotech
The 'diabolical' molecule set to become biotech's next gold rush
Should medicines that lower Lp(a) reach their full potential, they could spark a craze rivaling obesity and even surpass the success of statins.
Darren Incorvaia
Apr 9, 2026 8:00am
FDA illuminates new approval pathway for bespoke gene therapies
Feb 23, 2026 11:30am
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio
Apr 29, 2025 10:07am
After 11-month romance, GSK buys oligonucleotide partner Elsie
Jun 6, 2024 9:41am
